As the COVID-19 outbreak causes numerous supply chain disruptions, one lawyer warns that stakeholders throughout the drug supply chain could file a barrage of international arbitration claims, as contractual agreements involving active pharmaceutical ingredient manufacturers, shipping companies and finished drug suppliers are broken due to delays caused by the global spread of the novel coronavirus. Outside of the global drug supply chain, however, the lawyer says it’s unlikely that U.S. hospitals and health care suppliers will file arbitration claims against...